Terms: = Prostate cancer AND AFF3, MLLT2-like, 3899, ENSG00000144218, LAF4, P51826 AND Treatment
1 results:
1. A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
DiPaola RS; Chen YH; Stein M; Vaughn D; Patrick-Miller L; Carducci M; Roth B; White E; Wilding G
J Transl Med; 2010 Feb; 8():20. PubMed ID: 20178647
[TBL] [Abstract] [Full Text] [Related]